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Objective. The objective of this study was to compare perioperative, oncologic, and functional outcomes of TLPN (transperitoneal
laparoscopic partial nephrectomy) versus RLPN (retroperitoneal). Patients and Methods. From 1997 to 2009, a retrospective study
of 153 consecutive patients who underwent TLPN or RLPN for suspicious renal masses was performed. Complications, functional
and oncological outcomes were compared between the 2 groups. Results. With a mean followup of 39 and 32 months, respectively,
66 and 87 patients had TLPN and RLPN, respectively. Tumor location was more often posterior in the RLPN and more often
anterior in the TLPN. Mean operative time and mean hospital stay were longer in the TLPN group with 190 ± 85 min versus
154 ± 47 (P = 0.001) and 9.2 ± 6.4d a y sv e r s u s6 .2 ± 4.5d a y s( P<0.05), respectively. Transfusion and urinary ﬁstulas rates
were similar in the 2 groups. After 3-year followup, chronic kidney failure occurred in 6 and and 4% (P = 0.67) in after TLPN
and RLPN, respectively. After 3-year followup, recurrence free survival was 96.7% and 96.6% (P = 0.91) in the TLPN and RLPN
groups, respectively. Conclusion. Our study conﬁrmed that TLPN had longer operative time and hospital stay than RLPN. The
complication rates were similar. Furthermore, mid-term oncological and functional outcomes were similar.
1.Introduction
Renal cell carcinoma (RCC) represents 2-3% of all cancers.
It is the most lethal urologic cancer. Traditionally, more
than 40% of patients with RCC have died of their cancer,
in contrast with the 20% mortality rates associated with
prostate and bladder carcinomas [1]. In 2008, there were
an estimated 88 400 new cases and 39 300 kidney cancer-
related deaths from RCC in Europe [2]. Etiological factors
include lifestyle factors such as smoking, obesity, and
hypertension. Having a ﬁrst-degree relative with kidney
cancer is also associated with an increased risk of RCC. The
most eﬀective prophylaxis is to avoid cigarette smoking and
obesity [3]. Due to the increased detection of tumors by
imaging techniques, such as ultrasound (US) and computed
tomography (CT), the number of incidentally diagnosed
RCCs has increased. Currently, more than 50% of RCCs
are detected incidentally. These tumors are more often
smaller and of lower stage [4]. Surgery is the gold standard
treatment for localized RCC [3]. Nephron sparing surgery
(NSS) emerged as a new surgical approach for T1 RCC. The
rationaleforNSSistwofold.First,ithasbeenclearlyreported
that radical nephrectomy (RN) is associated with higher
mortality in pT1 RCC tumors [5] and more renal failure
[6]. Chronic kidney failure is independently associated with
higher mortality [7]. Second, NSS has the same oncological
outcomes than RN. Indications for NSS are absolute in cases
with an anatomic or functional solitary kidney, relative when
the functioning opposite kidney is aﬀected by a condition
that might impair renal function in the future, and elective
in the presence of a healthy contralateral kidney. Another
indication is patients with hereditary RCCs, who carry a
high risk of developing additional kidney tumors [3]. NSS
can be performed in opened (OPN), laparoscopic (LPN),
or with robotic-assisted surgery. The ﬁrst retroperitoneal
laparoscopic partial nephrectomy (RLPN) was reported by
Gill et al. in 1994 [8]. The transperitoneal laparoscopic
partial nephrectomy (TLPN) was ﬁrst reported by Winﬁeld
et al. in 1993 [9]. NSS can also be performed with robotic
assistance [10]. Compared to OPN, LPN is associated with2 Advances in Urology
similar renal function outcomes, decreased postoperative
narcotic use, shorter hospital stay, and improved convales-
cence [11]. Only few comparative TLPN and RPLN studies
have been reported. The objective of our study was to
compare perioperative, oncologic, and functional outcomes
of TLPN versus RLPN at our institution.
2. Patientsand Methods
2.1. Patients Selection. From 1997 to 2009, 153 consec-
utive patients underwent TLPN or RLPN for suspicious
renal masses. Data were obtained retrospectively from a
prospectively maintained database. Data collection and
review were approved by the Institutional Review Board.
All patients underwent chest and abdominal computed
tomography (CA-CT Scan) or magnetic resonance imag-
ing (MRI). Tumor location, depth of invasion into the
renal parenchyma, and relation to hilar structures were
determined preoperatively. NSS was indicated by one staﬀ
surgeon in small solitary tumors (elective), bilateral and
solitary kidney tumors (absolute). All procedures were
performed by three high-volume surgeons (LS, ADLT, and
CCA). The choice of the laparoscopic approach was at the
discretion of the surgeon, and it was dictated primarily by
the location and technical complexity of the renal mass. The
transperitoneal approach was generally used for anterior or
lateral lesions. The retroperitoneal approach was generally
used for posterior, posteromedial, or posterolateral lesions.
The American Society of Anesthesiologists (ASA) score was
used to evaluate comorbidities. The surgical parameters, the
perioperative complications, and functional and oncological
outcomeswerecomparedbetweenTLPNandRLPNpatients.
Surgical complications were graded according to the Clavien
score [12].
2.2. Surgical Technique. Our surgical technique for RLPN
has been detailed previously [13–15]. Gill’s technique was
used to perform TLPN [16]. When the kidney was entirely
dissected, a laparoscopic bull-dog clamp was introduced
to ensure warm ischemia. The excision of the tumor was
performed with sharp laparoscopic scissor with an adequate
margin. Control of transected intrarenal blood vessels and
pelvicaliceal repair were achieved with a central running
stitch. Parenchymal renorrhaphy was done with sutures tied
across an absorbable haemostatic bolster (Surgicel, Ethicon
France 92787 Issy Les Moulineaux) or/and a biological
hemostatic agent (GRF Biological Glue, Microval France,
Saint-Just-Malmont,France)orFloseal(BaxterFrance,Mau-
repas, France). Tumor excision and the entire renal suture
repair were performed in the ischemic kidney with the hilar
vessels clamped. A perirenal drain is left for 2 days. An
indwelling catheter is left for 1 day.
2.3. Followup. A medical examination was scheduled at
one and six months and then yearly. A CA-CT Scan was
performed during the followup according to the EAU Guide-
lines. The complications were reported with the Clavien
classiﬁcation system.
2.4. Data Collection and Statistical Analysis. Data were
collected into a database, including preoperative clinical
and biological characteristics, and patient demographics.
Quantitative data were tested using a Student t-test or a
Mann-Whitney test as appropriate. Qualitative data were
comparedusingaChi-squareoraFisher’stestasappropriate.
A double-sided P value <0.05 was considered statistically
signiﬁcant. The 5-year recurrence free survival was estimated
according to Kaplan Meier’s model, and survival curves were
testedusingalog-ranktest.AlldatawereanalyzedusingSPSS
v.16.0 software (SPSS, Chicago, IL, USA).
3. Results
NSS was indicated electively in 84% and 91%, for solitary
kidney in 11% and 6%, and for bilateral tumors in 5% and
3% in theTRLPandRLPNgroups,respectively. Preoperative
data are shown in Table 1. Tumor location was statistically
diﬀerent. In the TLPN and RLPN tumor groups, 60% and
28%(P<0.001)wereanteriorand13%and49%(P<0.001)
were posterior, respectively. Conversely, tumor size, location
pole, and the depth of the tumor in the renal parenchyma
were not signiﬁcatively diﬀerent.
There was a longer operative time in the TLPN group
(190 ± 85min versus 154 ± 47, P = 0.001). The others
peroperativeparametersareshowninTable 2.Con v ersionto
OPNwasreportedin4patients(kidneydissectiondiﬃculties
n = 2, peroperative bleeding n = 1, hilar tumor location
n = 1) and 3 patients (kidney dissection diﬃculties n = 2,
hilar control n = 1) in the anterior and posterior approach,
respectively.
Hospital stay was 9.2 ± 6.4d a y sa n d6 .2 ± 4.5d a y s
(P<0.05) in TLPN and RLPN, respectively. We had
an overall complication rate of 32% and 38% in TLPN
and RLPN groups, respectively. According to the Clavien
score, all grades of complications were comparable. Grade
I included wound infections and positive urinalysis during
the postoperative indwelling catheter period (TLPN n = 6
versus RLPN n = 7). All grade II complications were related
to blood transfusion. Hematoma was drained in 1 (1.5%)
and 2 (2.2%) patients and a double J stenting for urinary
ﬁstula was necessary in 3 (4.5%) and 4 (4.5%) patients
in TLPN and RLPN groups, respectively. The reported
grade IV complications, 3% in each group, were related
to a pulmonary thrombosis (RLPN n = 1) and acute
postoperative renal failure (TLPN n = 2v e r s u sR L P Nn =
2). Among them, one patient (1.1%) in the RLPN group
required a postoperative hemodialysis. Pathological ﬁndings
were similar in the 2 groups (Table 3).
After 3-year followup, chronic kidney failure occurred in
6 and in 4% (P = 0.67) after TLPN and RLPN, respectively.
Recurrence free-survival rates were not signiﬁcatively diﬀer-
ent in the 2 groups (Table 4, Figure 1).
4. Discussion
By 2000, because of the emerging data supporting elec-
tive PN, several minimally invasive surgery groups beganAdvances in Urology 3
Table 1: Baseline patients’ features and tumor characteristics.
TLPN RLPN P
No. pts 66 87
Mean age ± SD (years) 58 ± 13 59 ±11 0.80
Sex gender (%)
Male 57 67 0.15
Female 43 33
Mean ASA score ± SD 1.67 ± 0.62 1.55 ± 0.64 0.74
Mean preoperative serum creatinine ± SD (µmol/L) 99 ± 31 93 ± 32 0.27
Mean BMI ± SD (kg/m2) 24.99 ± 4.26 24.87 ± 3.92 0.75
Mean tumor size ± SD (cm) 2.64 ± 1.07 2.71 ± 1.25 0.67
Tumor location (%)
Anterior 60 28 <0.001
Posterior 10 49 <0.001
Lateral 8 23 0.15
Tumor pole (%)
Upper 38 22 0.18
Mid 24 37 0.38
Lower 38 41 0.72
Exophytic tumor mass (%)
>50% 10 14 0.39
Between 25% and 50 % 53 81 0.37
Endophytic 37 5 0.07
Median nephrometry score 7.15 6.09 0.03
Table 2: Perioperative data and complications.
TLPN RLPN P
No. pts 66 87
Mean operative time ± SD (min) 190 ± 85 154 ± 47 <0.001
Mean warm ischemia time ± SD (min) 47 ± 12 25 ± 9 <0.001
Mean estimated blood loss ± SD (mL) 254 ± 187 240 ± 213 0.87
Transfusion (%) 11 16 0.45
Ureteral stenting (%) 54 41 0.32
Parenchymal reparation (%)
Pledget 46 50 0.80
Pledget + bioadhesive agents 24 23 0.87
Bioadhesive agents 30 27 0.86
Open conversion (%) 5 5 0.90
Mean hospital stay ± SD (days) 9.2 ± 6.4 6.2 ± 4.5 <0.001
Complications (%)
Grade 1 10 12 0.67
Grade 2 11 16 0.44
Grade 3 8 7 0.75
Grade 4 3 3 0.89
Grade 5 0 0 0.90
concerted eﬀorts to develop LPN techniques intending to
closely simulate the open laparoscopic nephrectomy (OPN)
procedure. Among LPN, RLPN is less popular than TLPN.
Concerns about the continuing RLPN have been then arisen,
and many centers stopped performing this approach. In our
center, we usually use the laparoscopic retroperitoneal route
for various procedures including LPN [17]. However, our
staﬀ surgeons tend to prefer the transperitoneal approach.
Thus, we wanted to assess the surgical, functional, and
oncologic outcomes of the two procedures.
Regardless of the indication of the NSS, both TLPN
and RLPN can be performed for absolute or elective PN.4 Advances in Urology
Table 3
TLPN RLPN P
No. pts 66 87
Mean followup ± SD (months) 39 ± 30 32 ± 24 0.15
Renal failure (%) 6 4 0.67
Recurrence (%) 3.1 3.4 0.91
Lost of followup 2 4 0.78
Table 4
TLPN RLPN P
No. pts 66 87
Malignant tumor (%) 73 70 0.45
RCC 46 43
Papillary 27 23
Chromophobe 0 3
Other 0 1
Fuhrman grade (%)
11 5 1 3 0 . 8 7
26 7 6 4 0 . 7 8
31 8 2 3 0 . 6 7
Benign tumor (%) 27 30 0.77
Angiomyolipoma 14 17
Oncocytoma 8 9
Other 5 4
Positive margins (%) 5 3 0.45
However, posterior is likely to be treated with RLPN whereas
anterior tumors are treated with TLPN. Ng et al. [18]
compared 100 transperitoneal and 63 retroperitoneal LPNs
performed at their institution over a 3-year period. Case
selection was primarily based on tumor location, with 97%
of anterior tumors managed transperitoneally and 77% of
posterior tumors retroperitoneally. Larger tumors and those
that were deeply inﬁltrating were done transperitoneally
regardless of location. Patients undergoing transperitoneal
LPN had longer ischemia time (31 versus 28min; P = 0.04),
longer operative time (3.5 versus 2.9h; P<0.001), and
longer hospital stay (2.9 versus 2.2 days; P<0.01) com-
pared with retroperitoneal cases. Blood loss, perioperative
complications, and postoperative serum creatinine were not
statistically diﬀerent between groups. In concordance with
Wright and Porter [19], we did not ﬁnd any diﬀerence in
WIT (P = 0.3). Furthermore, we found the same results
about operative time and hospital stay in favor of the RLPN.
This may be due to a rapid access to the renal helium and
no mobilization of the bowl during TLPN which reduces the
postoperative ileus. Our overall complication rate may seem
high. However, only 3% were graded 4 and are comparable
to other studies. In a thorough report on 2775 urologic
laparoscopicproceduresthattookplaceatasingleinstitution
over 12 years, Permpongkosal et al. [20] reported on 345
patients who underwent LPN with an overall complication
rate of 28% and a major complication rate of 5.8%. Our
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Figure 1: Recurrence-free survival stratiﬁed by type of surgery.
transfusion rate and urine leakage are comparable to Gill’s
et al. experience [21].
Compared with OPN, LPN for T1A tumors had the
same oncologic results. In 2004, Allaf et al. reported on 48
patients who underwent TLPN for pathologically proven
renal cell carcinoma [22]. Mean tumor size was 2.4cm, and
ﬁnal pathologic stage was pT1 in 88% and pT3a in 12%.
No recurrences were observed in 96% of patients. Recently,
Lane et al. [23] reported a long-term oncological outcome
of the PN. They found that 97% and 93% patients were
free of metastasis after 5 and 7-year followup. The approach
for the LPN was not reported. However, the data were
comparable with OPN. In previously published comparative
series [18, 19, 24], the TLPN and RLPN were similar in
terms of oncological outcomes. Our study conﬁrmed these
results.
Our study is limited by the retrospective aspects of
the analysis of a prospectively collected data. Besides, the
study is not randomized. The choice of TLPN or RLPN is
totally dependent of the surgeon’s conﬁdence and strategy.
A randomized trial would give a high evidence answer to
this question. Another important issue is the limited spread
of RLPN. Gills et al. reported 32.6% of RLPN his ﬁrst era’s
experience of LPN. This rate dropped to 20.8% and 1.3%
in his second and third eras, respectively [21]. This may be
due to the unusual anatomical presentation of the RLPN
and a larger working space of the anterior approach. Recent
years witnessed the development of the robotic-assisted PN
[25, 26]. To date, the transperitoneal approach for the robot
is mandatory. Therefore, we think the RLPN will remain
unpopular. However, this approach should be considered
in some patient. In fact, the risk of bowel or other intra-
abdominal organ injury is dramatically reduced, and, in
patients with prior intra-abdominal surgery, the need for
lysis of adhesions can be avoided entirely.Advances in Urology 5
5. Conclusion
OurstudyconﬁrmedthereporteddatathatTLPNandRLPN
were similar except for the operative time and the hospital
stay longer in the TLPN. However, even if the RLPN is not
as popular as TLPN, this approach should be considered for
few patients with past history of intraperitoneal procedures
that may turn the TLPN to be more diﬃcult than RLPN.
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